Anchorage, AKNCT03866382Now EnrollingIRB Ready

Rare Genitourinary Tumors Clinical Trial in Anchorage, AK

Access cutting-edge rare genitourinary tumors treatment through this clinical trial at a research site in Anchorage. Study-provided care at no cost to qualified participants.

Sponsored by National Cancer Institute (NCI)

Quick Self-Assessment

See if you qualify for this Anchorage location

Preparing your pre-screening questions...

Expert Care in Anchorage

Access rare genitourinary tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related rare genitourinary tumors treatment provided free

Apply for This Anchorage Location

Check if you qualify for this rare genitourinary tumors clinical trial in Anchorage, AK

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Anchorage

    Convenient for AK residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Anchorage site if eligible
  4. 4Begin participation

About This Rare Genitourinary Tumors Study in Anchorage

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere wit

Sponsor: National Cancer Institute (NCI)

Who Can Participate

Inclusion Criteria

Metastatic disease defined as new or progressive lesions on cross-sectional imaging or bone scan. Patients must have at least:
One measurable site of disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
One bone lesion on bone scan (tec99 or sodium fluoride \[NaF\] PET/CT, CT or MRI) for the bone-only cohort.
Histologically confirmed diagnosis of one of the following metastatic cohorts:
Small cell/ neuroendocrine carcinoma of the bladder (Cohort A)- All urothelial carcinomas with any amount of neuroendocrine differentiation (including small cell differentiation) will be included. If the tumor is purely neuroendocrine, metastasis from another site of origin should be clinically excluded
Adenocarcinoma of the bladder, or urachal adenocarcinoma, or bladder/urethra clear cell adenocarcinoma (Cohort B) - must be pure (per World Health Organization \[WHO\] definition), (i.e. urothelial carcinoma with glandular d

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Anchorage?

Yes, this clinical trial (NCT03866382) has an active research site in Anchorage, AK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Rare Genitourinary Tumors Treatment Options in Anchorage, AK

If you're searching for rare genitourinary tumors treatment options in Anchorage, AK, this clinical trial (NCT03866382) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Anchorage research site is actively enrolling participants for this clinical trial. You'll receive care from experienced rare genitourinary tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all rare genitourinary tumors clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Anchorage, AK

See all rheumatoid arthritis clinical trials recruiting in Anchorage — not just this study.

Browse Rheumatoid Arthritis Trials in Anchorage

Browse More Trials by Condition

Ready to Join in Anchorage?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Anchorage, AK